Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 8/20 | 0.37 |
| ▸ | ACHE | P22303 | 8/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331366 | 0.89 | OPRD1 (0.41) | MEN1KMT2AOPRD1OPRK1OPRM1 | |
| SCHEMBL4341393 | 0.78 | CHRM5 (0.40) | MEN1KMT2ACHRM5BCHEALDH1A1 | |
| SCHEMBL5317078 | 0.74 | KDM4E (0.50) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4331215 | 0.73 | BCHE (0.44) | BCHEACHECCR5 | |
| SCHEMBL4327141 | 0.72 | OPRM1 (0.55) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4340798 | 0.71 | MGLL (0.41) | MEN1KMT2AOPRD1ALDH1A1 | |
| SCHEMBL4322972 | 0.71 | KDM4E (0.39) | CCR5ALDH1A1 | |
| SCHEMBL4323029 | 0.68 | HDAC4 (0.43) | OPRD1OPRK1CCR5OPRM1 | |
| SCHEMBL4325746 | 0.67 | LMNA (0.48) | MEN1KMT2AOPRD1OPRK1OPRM1 | |
| SCHEMBL4330985 | 0.65 | SMN1; SMN2 (0.44) | OPRD1OPRK1OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | MEN1 3300/4885CRHBP 901/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.